Addendum
Lisocabtagene maraleucel (DLBCL, HGBL, PMBCL and FL3B, second line) – Addendum to Commission A23-48
Report documents
-
Addendum
Lisocabtagene maraleucel (DLBCL, HGBL, PMBCL and FL3B, second line) – Addendum to Commission A23-48
Dossier assessment
Adults with diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma or follicular lymphoma grade 3B, who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy
- Patients < 65 years who are eligible for high-dose therapy: indication of major added benefit
- Patients ≥ 65 years who are eligible for high-dose therapy: indication of considerable added benefit
- Patients with diffuse large B-cell lymphoma or high-grade B-cell lymphoma who are not eligible for high-dose therapy: added benefit not proven
- Patients with primary mediastinal large B-cell lymphoma or follicular lymphoma grade 3B who are not eligible for high-dose therapy: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2023-11-16 A G-BA decision was published.
Project details
- Project no.
- A23-98
- Commission
- Commission awarded on 11.10.2023 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://dx.doi.org/10.60584/A23-98
Connected Projects
-
Dossier assessment
Lisocabtagene maraleucel (DLBCL, HGBCL, PMBCL and FL3B, each after one prior therapy) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Lisocabtagene maraleucel (mantle cell lymphoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed